Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1993-02-05
2003-12-02
Helms, Larry Ronald (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100
Reexamination Certificate
active
06657050
ABSTRACT:
BACKGROUND OF THE INVENTION
The use of monoclonal antibodies for therapy has gained increasing interest in recent years. The ability to influence an individual's immune state by administering immunoglobulin of appropriate specificity has been considered a powerful approach to disease control and prevention. Therapeutic efficacy of certain monoclonal antibodies in anti-tumor treatment has been documented. See e.g., Sears, H. F. et al., (1984)
J. Biol. Resp. Modif.
3:138.
Viral specific antibodies can be therapeutically useful for treatment of viral infections. Antibodies directed against some components of a virus can neutralize the virus. Antibodies which fix complement (C1-C9) cause lysis of cells carrying viral antigens or directly damage enveloped viruses. Furthermore, antibodies that bind to Fc receptors on the surface of phagocytic cells can also cause antibody-dependent cell-mediated cytotoxicity of virus-infected cells.
Recently, monoclonal antibodies have been developed against the exterior glycoprotein gp120 of the human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS). See, Fung, S. C. et al.,
BioTechnology
5:940 (1987). The antibodies are capable of inhibiting the infection of susceptible T cells by free virions. The antibodies also inhibit the fusion between HIV-infected cells and uninfected cells which results in the formation of multinucleated giant cells (syncytia), a mechanism implicated as a major route of viral transmission and T cell death. These HIV-neutralizing antibodies have applications in therapy and prevention of AIDS.
Most presently available monoclonal antibodies, including antiviral monoclonal antibodies, are murine antibodies. The production of human antibodies by somatic cell fusion is generally difficult. Techniques for production of monoclonal antibodies in the mouse, however, are well established and allow for preparation of monoclonal antibodies against virtually any antigen.
Murine antibodies, however, have several drawbacks which impede their use in human therapy. As foreign proteins, murine antibodies often evoke counteracting immune reactions which may reduce or destroy their therapeutic effectiveness. In addition, murine antibodies can elicit allergic or hypersensitivity reactions in patients. Unfortunately, the need for readministration in therapy increases the likelihood that these immune reactions will occur in patients.
One way to ameliorate the problems associated with the in vivo use of a murine antibody is to convert the murine antibody to a “chimeric” antibody. The chimeric antibody consists of the variable region of the murine antibody joined to a human constant region. See, e.g., Morrison, S. L. et al. (1984) “Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains”
Proc. Natl. Acad. Sci. USA
81:6851; Neuberger, M. S. and Rabbits, T. H. “Production of Chimeric Antibodies” PCT Application No. PCT/GB85 00392. Because the chimeric antibody has a human constant region (the region which is largely responsible for inducing immune response against antibody), it is less likely to evoke an anti-murine immune response in humans. Furthermore, the human constant region may provide for an antibody with a longer half life and better effector function in humans.
A number of studies have described chimeric murine/human immunoglobulins. See, e.g., Sun, L. K. et al., (1987)
Proc. Natl. Acad. Sci. USA
84:214; Liu, A. Y. et al., (1987)
J. Immunol.
139:3521; Sahagan, B. G. et al., (1986)
J. Immunol.
137:1066, Liu, A. Y. et al., (1987)
Proc. Natl. Acad. Sci. USA
84:3439.
SUMMARY OF THE INVENTION
This invention pertains to chimeric viral neutralizing immunoglobulins, particularly HIV-neutralizing immunoglobulins, comprising a viral-specific antigen binding (variable) region of nonhuman origin and a constant region of human origin. The chimeric immunoglobulins, prepared by genetic engineering techniques, retain the viral neutralizing activity of the parent, nonhuman immunoglobulin from which they are derived. The chimeric immunoglobulins are useful for immuno-therapy of viral-mediated diseases such as AIDS.
REFERENCES:
patent: 4664911 (1987-05-01), Uhr et al.
patent: 4725669 (1988-02-01), Essex et al.
patent: 0125023 (1984-04-01), None
patent: 0129434 (1984-06-01), None
patent: 0171496 (1985-03-01), None
patent: 0171496 (1986-02-01), None
patent: 0193284 (1986-03-01), None
patent: 0214709 (1986-04-01), None
patent: 0185444 (1986-06-01), None
patent: 0199301 (1986-10-01), None
patent: 0248534 (1987-05-01), None
patent: 0295803 (1988-12-01), None
patent: 2137631 (1984-03-01), None
patent: 2196634 (1991-05-01), None
patent: WO86/01533 (1985-09-01), None
patent: 8601533 (1986-03-01), None
patent: WO86/02383 (1986-04-01), None
patent: WO87/02775 (1987-05-01), None
patent: WO87/02671 (1987-07-01), None
Liou et al. Journal of Immunology 143 3967-3975 1989.*
TiBTECH Feb. 1993 vol. 11, p. 42.*
Legrain et al. J. Virology 60:1141-1144 1986.*
Morrison, S.L., Science vol. 229 pp. 1203-1207, 1985.*
Robey et al. PNAS USA vol. 83 pp 7023-7027, 1986.*
Lasky et al. Science vol. 223, pp 209-212, 1986.*
Chanh et al. Eur. J. Immunol. 16: 1465-68 1986.*
Lafon et al. J. Gen. Virol. 64: 8431-51 1983.*
Dreesman et al. J. Cellular Biochem, Suppl. 11D 1987 p. 34.*
McDougal et al. “HIV Binding to CD21 Molecule . . . ” J. Cellular Biochemistry Supp.11D (1987).
Gosting et al. “Monoclonal Antibodies to 8P110 and gp 41 . . . ” J Clinical Microbiology 25(5) 845-848 1987.
M. Robert-Guroff, et al.,Nature, 316: 72-74 (1985).
Weiss et al. “Variable and Conserved Neutralization Antigens of Human Immunodeficiency Virus” Nature 324: 572-75 (1986).
Ho et al. “Human Immunodeficiency Virus Neutralizing Antibodies Recognize Several Conserved Domains on the Envelope Glycoproteins” J. Virol. 2024-8 (1987).
J.D. Lifson et al.,Nature, 323: 725-728 (1986).
S.D. Putney, et al.,Science, 234: 1392-1395 (1986).
Gottlieb et al. Current Typics in AIDS; Chapter 12 (1987).
“Expression of the Fusion Protein of Human Respiratory Syncytial Virus from Recombinant Vaccinia Virus Vectors and Protection of Vaccinated Mice,” vol. 61, No. 2 Journal of Virology 293-301 (1987); G.W. Wertz et al.
“Expression of the HTLV-III Envelope Gene by a Recombinant Vaccinia Virus,” 320 Nature 535-540 (1986): S. Chakrabarti et al.
“Binding of HTLV-III/LAV to T4+ T Cells by a Complex of the 110k Viral Protein and the T4 Molecule,” 232 Science 382-385 (1986); J.S. McDougal et al.
“Neutralization of Human T-Lymphotropic Virus Type III by Sera of AIDA and AIDS-Risk Patients,” 316 Nature 69-72 (1985); Weiss et al.
“Neutralization of HTLV-III/LAV Replication by Antiserum to Thymosin alpha1,” 232 Science 1135-1137 (1986); Sarin et al.
“Human Immunodeficiency Virus Contains an Epitope Immunoreactive with Thymosin Alpha1and the 30-Amino and Synthetic p17 Group-Specific Antigens Peptide HGP-30,” 84 Proc. Natl. Acid. Sci. USA 2951-55 H. Naylor, et al.
“AIDS Virus ENV Protein Expressed From a Recombinant Vaccinia Virus,” 4 Bio/Technology 790-795 (1986); M.P. Kieny et al.
“The CD4 (T4) Antigen is an Essential Component of the Receptor for the AIDS Retrovirus,” 312 Nature 763-67 (1984); Dagleish et al.
“Role of the HTLV-III/LAV Envelope in Syncytium Formation and Cytopathicity,” 322 Nature 470-474 (1986); Sodroski et al.
“Chimeric Antibodies with 17-1A-Derived Variable and Human Constant Regions,” 5 Hybridoma Suppl. 1 (1986); L.K. Sun et al.
“Chimeric Antibodies,” vol. 4 No. 3 Biotechniques 214-221 (1986); V.T. Oi & S.L. Morrison
“T-Lymphocyte Priming and Protection Against Friend Leukemia by Vaccinia-Retrovirus env Gene Recombinant,” 234 Science 728-731 (1986) : P.L. Earl, et al.
“A Chemical Technique for the Preparation of Bispecific Antibodies from Fab Fragments of Mouse Monoclonal IgG1,” Vol 4 No 5 Biotechniques 424-427 (1986) M. Brennan.
“Restricted Neutralization of Divergent Human T-Lymphotropic Virus Type III Isolates by Antibodies to the Major Envelope Glycoprotein,” 83 Pro. Natl. Acad. Sci. USA 9709-9713 (1986); Mathews
Chang Nancy T.
Chang Tse Wen
Fung Michael S. C.
Sun Bill N. C.
Sun Cecily R. Y.
Helms Larry Ronald
Liljestrand Cheryl A.
Tanox, Inc.
LandOfFree
Chimeric viral-neutralizing immunoglobulins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric viral-neutralizing immunoglobulins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric viral-neutralizing immunoglobulins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3183297